{
  "case_id": "MN23-38795",
  "year": 2023,
  "patient_info": {
    "age_range": "21 to 30",
    "gender": "Male"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [
    "Chronic Kidney Disease",
    "Proteinuria"
  ],
  "complications": [],
  "symptoms": [],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Other",
  "treatments_requested": [
    {
      "name": "Lupkynis",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_tried_but_failed": [],
  "treatments_tried_and_worked": [
    {
      "name": "Hydroxychloroquine",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Mycophenolate Mofetil",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Lupkynis",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_not_tried": [],
  "is_denial_upheld": false,
  "issues_considered": [
    "medical_necessity",
    "plan_coverage"
  ],
  "other_issues": null,
  "guidelines_support": true,
  "guidelines_not_support": null,
  "guidelines_details": "Per the American College of Rheumatology (ACR) guidelines, continuing Lupkynis is appropriate for this patient.",
  "soc_support": true,
  "soc_not_support": null,
  "soc_details": "The U.S. Food and Drug Administration (FDA) has approved Lupkynis to be used with other medications to treat patients with active lupus nephritis.",
  "study_support": true,
  "study_details": [
    {
      "study_name": "Study on Lupkynis efficacy",
      "study_authors": "Not specified",
      "key_findings": "Addition of low-dose Lupkynis to mycophenolate mofetil and corticosteroids results in a superior renal response compared to mycophenolate mofetil and corticosteroids alone."
    }
  ],
  "key_questions": [
    "medical_necessity",
    "plan_coverage"
  ],
  "expedited": true,
  "rationale": "The requested Lupkynis 7.9 mg is medically necessary for treatment of this patient\u2019s medical condition. The Health Plan\u2019s denial should be overturned.",
  "reviewer_credentials": "Board certified in internal medicine with subspecialty certification in nephrology, actively practicing, expert in the treatment of the enrollee\u2019s medical condition."
}